Critical Care

official impact factor 4.60

Download references

Conclusions regarding the efficacy of treatments for neuroleptic malignant syndrome should be tempered given poor quality data, regardless of the analysis conducted

Darren M Roberts* and Jason A Roberts

Critical Care 2007, 11:413 doi:10.1186/cc5786

Include


Format